Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response

L. Makowka, C. Miller, P. Chapchap, L. Podesta, C. Pan, D. Pressley, V. Mazzaferro, C. O. Esquivel, S. Todo, B. Banner, R. Jaffe, R. Saunders, T. E. Starzl

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The pathogenesis of hyperacute renal rejection consists of a nonspecific effector cascade that invokes most of the components of a typical acute inflammatory response. Platelet-activating factor (PAF) represents the most recent and perhaps the most significant mediator and promoting agent of this phenomenon. These studies evaluated SRI 63-441, a novel, synthetic, and the most potent PAF receptor antagonist available, alone and in combination with other prostanoids, for their ability to influence this response and to prolong renal xenograft survival and function in a model of pig-to-dog heterotransplantation. Inhibition of PAF by SRI 64-441 alone, at the dosage and schedule used in these experiments, did not significantly prolong xenograft survival or function. However, the combination of SRI 63-441 with either prostacyclin (PGI2) or prostaglandin E1 (PGE1) infusion demonstrated significant synergism, and resulted in a 6-9-fold increase in kidney survival and a 3-20-fold increase in urine output. Neither PGI2 nor PGE1 infusions alone significantly influenced this xenograft model. Electromagnetic flow studies demonstrated significantly delayed diminution in renal artery blood flow in the combination-treated animals. Serial and end-stage histologic examination of kidneys receiving combination therapy demonstrated a delayed onset of the pathologic deterioration and an overall amelioration of the entire process. These studies demonstrate that significant abrogation of a rapid and violent form of the hyperacute rejection can be achieved solely by the pharmacologic manipulation of the inflammatory mediator response.

Original languageEnglish
Pages (from-to)482-495
Number of pages14
JournalAnnals of Surgery
Volume206
Issue number4
Publication statusPublished - 1987

Fingerprint

Heterografts
Epoprostenol
Swine
Dogs
Kidney
Alprostadil
Platelet Activating Factor
Renal Circulation
Electromagnetic Phenomena
Renal Artery
Prostaglandins
Appointments and Schedules
Urine
SRI 63-441
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Makowka, L., Miller, C., Chapchap, P., Podesta, L., Pan, C., Pressley, D., ... Starzl, T. E. (1987). Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. Annals of Surgery, 206(4), 482-495.

Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. / Makowka, L.; Miller, C.; Chapchap, P.; Podesta, L.; Pan, C.; Pressley, D.; Mazzaferro, V.; Esquivel, C. O.; Todo, S.; Banner, B.; Jaffe, R.; Saunders, R.; Starzl, T. E.

In: Annals of Surgery, Vol. 206, No. 4, 1987, p. 482-495.

Research output: Contribution to journalArticle

Makowka, L, Miller, C, Chapchap, P, Podesta, L, Pan, C, Pressley, D, Mazzaferro, V, Esquivel, CO, Todo, S, Banner, B, Jaffe, R, Saunders, R & Starzl, TE 1987, 'Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response', Annals of Surgery, vol. 206, no. 4, pp. 482-495.
Makowka L, Miller C, Chapchap P, Podesta L, Pan C, Pressley D et al. Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. Annals of Surgery. 1987;206(4):482-495.
Makowka, L. ; Miller, C. ; Chapchap, P. ; Podesta, L. ; Pan, C. ; Pressley, D. ; Mazzaferro, V. ; Esquivel, C. O. ; Todo, S. ; Banner, B. ; Jaffe, R. ; Saunders, R. ; Starzl, T. E. / Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. In: Annals of Surgery. 1987 ; Vol. 206, No. 4. pp. 482-495.
@article{2ca45519dce84542a9bc9fb81969859d,
title = "Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response",
abstract = "The pathogenesis of hyperacute renal rejection consists of a nonspecific effector cascade that invokes most of the components of a typical acute inflammatory response. Platelet-activating factor (PAF) represents the most recent and perhaps the most significant mediator and promoting agent of this phenomenon. These studies evaluated SRI 63-441, a novel, synthetic, and the most potent PAF receptor antagonist available, alone and in combination with other prostanoids, for their ability to influence this response and to prolong renal xenograft survival and function in a model of pig-to-dog heterotransplantation. Inhibition of PAF by SRI 64-441 alone, at the dosage and schedule used in these experiments, did not significantly prolong xenograft survival or function. However, the combination of SRI 63-441 with either prostacyclin (PGI2) or prostaglandin E1 (PGE1) infusion demonstrated significant synergism, and resulted in a 6-9-fold increase in kidney survival and a 3-20-fold increase in urine output. Neither PGI2 nor PGE1 infusions alone significantly influenced this xenograft model. Electromagnetic flow studies demonstrated significantly delayed diminution in renal artery blood flow in the combination-treated animals. Serial and end-stage histologic examination of kidneys receiving combination therapy demonstrated a delayed onset of the pathologic deterioration and an overall amelioration of the entire process. These studies demonstrate that significant abrogation of a rapid and violent form of the hyperacute rejection can be achieved solely by the pharmacologic manipulation of the inflammatory mediator response.",
author = "L. Makowka and C. Miller and P. Chapchap and L. Podesta and C. Pan and D. Pressley and V. Mazzaferro and Esquivel, {C. O.} and S. Todo and B. Banner and R. Jaffe and R. Saunders and Starzl, {T. E.}",
year = "1987",
language = "English",
volume = "206",
pages = "482--495",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response

AU - Makowka, L.

AU - Miller, C.

AU - Chapchap, P.

AU - Podesta, L.

AU - Pan, C.

AU - Pressley, D.

AU - Mazzaferro, V.

AU - Esquivel, C. O.

AU - Todo, S.

AU - Banner, B.

AU - Jaffe, R.

AU - Saunders, R.

AU - Starzl, T. E.

PY - 1987

Y1 - 1987

N2 - The pathogenesis of hyperacute renal rejection consists of a nonspecific effector cascade that invokes most of the components of a typical acute inflammatory response. Platelet-activating factor (PAF) represents the most recent and perhaps the most significant mediator and promoting agent of this phenomenon. These studies evaluated SRI 63-441, a novel, synthetic, and the most potent PAF receptor antagonist available, alone and in combination with other prostanoids, for their ability to influence this response and to prolong renal xenograft survival and function in a model of pig-to-dog heterotransplantation. Inhibition of PAF by SRI 64-441 alone, at the dosage and schedule used in these experiments, did not significantly prolong xenograft survival or function. However, the combination of SRI 63-441 with either prostacyclin (PGI2) or prostaglandin E1 (PGE1) infusion demonstrated significant synergism, and resulted in a 6-9-fold increase in kidney survival and a 3-20-fold increase in urine output. Neither PGI2 nor PGE1 infusions alone significantly influenced this xenograft model. Electromagnetic flow studies demonstrated significantly delayed diminution in renal artery blood flow in the combination-treated animals. Serial and end-stage histologic examination of kidneys receiving combination therapy demonstrated a delayed onset of the pathologic deterioration and an overall amelioration of the entire process. These studies demonstrate that significant abrogation of a rapid and violent form of the hyperacute rejection can be achieved solely by the pharmacologic manipulation of the inflammatory mediator response.

AB - The pathogenesis of hyperacute renal rejection consists of a nonspecific effector cascade that invokes most of the components of a typical acute inflammatory response. Platelet-activating factor (PAF) represents the most recent and perhaps the most significant mediator and promoting agent of this phenomenon. These studies evaluated SRI 63-441, a novel, synthetic, and the most potent PAF receptor antagonist available, alone and in combination with other prostanoids, for their ability to influence this response and to prolong renal xenograft survival and function in a model of pig-to-dog heterotransplantation. Inhibition of PAF by SRI 64-441 alone, at the dosage and schedule used in these experiments, did not significantly prolong xenograft survival or function. However, the combination of SRI 63-441 with either prostacyclin (PGI2) or prostaglandin E1 (PGE1) infusion demonstrated significant synergism, and resulted in a 6-9-fold increase in kidney survival and a 3-20-fold increase in urine output. Neither PGI2 nor PGE1 infusions alone significantly influenced this xenograft model. Electromagnetic flow studies demonstrated significantly delayed diminution in renal artery blood flow in the combination-treated animals. Serial and end-stage histologic examination of kidneys receiving combination therapy demonstrated a delayed onset of the pathologic deterioration and an overall amelioration of the entire process. These studies demonstrate that significant abrogation of a rapid and violent form of the hyperacute rejection can be achieved solely by the pharmacologic manipulation of the inflammatory mediator response.

UR - http://www.scopus.com/inward/record.url?scp=0023620482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023620482&partnerID=8YFLogxK

M3 - Article

VL - 206

SP - 482

EP - 495

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -